AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Biotage Regulatory Filings 2017

Jan 2, 2017

2894_rns_2017-01-02_16be5fdc-62de-48b2-8a61-e92a1b3de5ac.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

Press release Biotage AB

Contact persons: SE-751 03 Uppsala Torben Jörgensen, CEO Tel:018 56 59 00 Tel: +46 707 490584, [email protected] www.biotage.com Erika Söderberg-Johnson, CFO Tel: +46 707 204820, [email protected]

Box 8

Uppsala January 2, 2017

Biotage's shares now traded on the Mid Cap segment of Nasdaq OMX Nordic

As from today, Biotage AB (BIOT.ST) change segment at Nasdaq OMX Nordic, from the Small Cap Segment to the Mid Cap Segment.

About Biotage

Biotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage's products are used by government authorities, academic institutions, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan and South Korea. Biotage has approx. 320 employees and had sales of 611 MSEK in 2015. Biotage is listed on the NASDAQ OMX Nordic stock exchange. Website: www.biotage.com